863028-97-1Relevant articles and documents
HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
-
Paragraph 0553, (2021/01/23)
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives
Hisamichi, Hiroyuki,Naito, Ryo,Toyoshima, Akira,Kawano, Noriyuki,Ichikawa, Atsushi,Orita, Akiko,Orita, Masaya,Hamada, Noritaka,Takeuchi, Makoto,Ohta, Mitsuaki,Tsukamoto, Shin-Ichi
, p. 4936 - 4951 (2007/10/03)
Spleen tyrosine kinase (Syk) is a non-receptor-type tyrosine kinase which mediates diverse responses in haematopoietic cells. Therefore, Syk is an attractive therapeutic target, and in a study of Syk inhibitors as potentially new therapeutic agents, we di